A5036374373- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- BRCA gene mutations in cancer
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Multiple and Secondary Primary Cancers
- Chronic Lymphocytic Leukemia Research
- Photoacoustic and Ultrasonic Imaging
- Sarcoma Diagnosis and Treatment
- Proteoglycans and glycosaminoglycans research
- Cancer Cells and Metastasis
- DNA Repair Mechanisms
- Chemotherapy-induced cardiotoxicity and mitigation
- Estrogen and related hormone effects
- Angiogenesis and VEGF in Cancer
- Radiomics and Machine Learning in Medical Imaging
- Fibroblast Growth Factor Research
- Vitamin D Research Studies
- Musculoskeletal pain and rehabilitation
Washington University in St. Louis
2013-2025
University of Puerto Rico at Carolina
2025
Financial Research Institute of the Ministry of Finance of the Russian Federation
2025
Georgia Institute of Technology
2025
Dauphin Island Sea Lab
2021
University of South Alabama
2021
University of Arkansas for Medical Sciences
2006
Abstract Purpose: Clinical biomarkers to identify patients unlikely benefit from CDK4/6 inhibition (CDK4/6i) in combination with endocrine therapy (ET) are lacking. We implemented a comprehensive circulating tumor DNA (ctDNA) analysis genomic features for predicting and monitoring treatment resistance. Experimental Design: ctDNA was isolated 216 plasma samples collected 51 hormone receptor–positive (HR+)/HER2-negative (HER2−) metastatic breast cancer (MBC) on phase II trial of palbociclib...
Abstract Purpose: Clinical tools to monitor treatment response and metastatic risk could improve early-stage triple-negative breast cancer (TNBC) care. While molecular residual disease (MRD) assays show promise, their use in the neoadjuvant setting requires rapid turnaround times. Tissue-informed approaches may be challenging for patients with limited biopsy samples. The objectives were determine surveillance sensitivity detecting recurrence evaluate ctDNA therapy using a tissue-free...
Background: Cyclin-dependent kinase (CDK) 4/6 inhibitors are now the standard of care for hormone receptor-positive (HR+), HER2-negative (HER-) metastatic breast cancer (MBC). However, guidelines lacking regarding their optimal sequencing with other available agents. This study examines physician practice patterns and treatment outcomes palbociclib subsequent therapies in a real-world setting. Methods: A retrospective chart review was conducted consecutive patients MBC who received between...
Targeting tumor-associated macrophages through C-C chemokine receptor type 2 (CCRs) in pancreatic ductal adenocarcinoma (PDAC) improves the efficacy of chemotherapy and restores T cell immunity preclinical models. We conducted a phase I/II single institution study (NCT03496662) combining gemcitabine nab-paclitaxel (GnP), CCR2/5 inhibitor BMS-813160 nivolumab for four 28-day cycles patients with borderline resectable (BR) or locally advanced (LA) PDAC. The recommended dose (RP2D) was...
Creative solutions are needed to enhance mobility activities in the ICU combat sequela of prolonged bed rest. Virtual reality has gained favor for use outpatient areas, yet user experience patient is relatively unknown. This qualitative study aimed explore as it relates critically ill patient. Human-centered design methodology was used generate a list needs. Analysis revealed need progressive that builds on standard rehabilitation practices with dynamic elements balance stimulation and...
Abstract Background: CDK4/6 inhibitors (CDK4/6i) have revolutionized HR+ metastatic breast cancer treatment. Trials like PALOMA, MONALEESA, and MONARCH showed improved progression-free survival (PFS) with endocrine therapy (ET), establishing it as first-line Bone metastases are common in cancer, 40% of patients having bone-only disease (BoD), which has a distinct course better prognosis. However, CDK4/6i trials less significant PFS benefits BoD subgroups. This study explores outcomes...
Abstract Patients with ER+/HER2+ breast cancer (BC) are less likely to achieve pathological complete response (pCR) after chemotherapy dual HER2 blockade than ER−/HER2+ BC. Endocrine therapy plus trastuzumab is effective in advanced Inhibition of CDK4/6 and results synergistic cell proliferation reduction. We combined palbociclib, letrozole, (PLT) as a chemotherapy-sparing regimen. evaluated neoadjuvant PLT early Primary endpoint was pCR 16 weeks. Research biopsies were performed for whole...
Abstract Palbociclib 3-weeks-on/1-week-off, combined with hormonal therapy, is approved for hormone receptor positive (HR+)/HER2-negative (HER2−) advanced/metastatic breast cancer (MBC). Neutropenia the most frequent adverse event (AE). We aim to determine whether an alternative 5-days-on/2-days-off weekly schedule reduces grade 3 and above neutropenia (G3 + ANC) incidence. In this single-arm phase II trial, patients HR+/HER2− MBC received palbociclib 125 mg, 5-days-on/2-days-off, plus...
To report the interim analysis of phase II single-arm noninferiority trial, testing upfront use dexrazoxane with doxorubicin on progression-free survival (PFS) and cardiac function in soft-tissue sarcoma (STS).
Abstract Background: CDK4/6 inhibitors (CDK 4/6i) have significantly advanced the treatment of hormone receptor-positive (HR+) metastatic breast cancer in last decade. Several clinical trials including PALOMA, MONALEESA, and MONARCH shown improved progression-free survival (PFS) rates when CDK4/6i were combined with endocrine therapy (ET). These results led to recommending their use combination ET as first line settings. Bone metastasis is most common site disease patients HR+ cancer, about...
1016 Background: The ph III EMBRACE trial of E vs physician’s choice tx led to FDA approval as ≥3rd-line for MBC pts with prior exposure anthracyclines/taxanes. BOLD 301 capecitabine in advanced BC treated anthracyclines/taxanes showed a nonsignificant trend improved median OS all pts; pre-planned analysis by HER2 status revealed nominally significant benefit HER2- pts. Methods: RU011201I is an investigator initiated 1:1 randomization (1.4 mg/m2 D1,8 q21days) P (90 D1,8,15 q28days) within...
Abstract Background: KEYNOTE-522 was a randomized, double-blind, placebo-controlled phase 3 trial which resulted in the FDA approval of pembrolizumab with neoadjuvant chemotherapy for patients (pts) newly diagnosed, high-risk, early-stage triple negative breast cancer (TNBC). Given improvement pathological complete response (pCR) and event-free survival rates, this regimen has emerged as standard-of-care (SOC) therapy. Adverse events pts on treatment clinical practice is unknown...
Abstract Background Patients (pts) with ER+ HER2+ breast cancer (BC) are less likely to achieve pathological complete response (pCR) after neoadjuvant chemotherapy dual HER2 blockade than pts ER- BC. Endocrine therapy (ET) plus trastuzumab is effective in advanced BC, but pCR rate low the setting. Inhibition of CDK4/6 and results synergistic reduction cell proliferation preclinical studies. We therefore combined ET inhibition BC as a chemotherapy-sparing regimen. Methods evaluated efficacy...
Abstract Introduction: Palbo is approved in combination with an aromatase inhibitor or fulvestrant (FUL) for the treatment of HR+ HER2- MBC. The incidence grade (G) 3/4 neutropenia (ANC) approaching 66% has been observed phase 3 trials palbo. We hypothesize that alternative schedule palbo, 5 days on/2 off every 7 days, reduces severity neutropenia, therefore allowing continued weekly dosing and less dose reduction discontinuation. Methods: A single arm II study (Alt Dose Palbo) was conducted...
Abstract Background: CDK4/6 inhibitors (CDK4/6i) paired with endocrine therapy (ET) are considered first-line (1L) for patients (pts) HR+ HER2- advanced breast cancer (aBC). A minority of pts will demonstrate primary resistance to CDK4/6i, as characterized by early progression. Thymidine kinase 1 (TK1) is a cell-cycle regulated enzyme downstream and involved in nucleotide metabolism during DNA synthesis. Prior studies have shown TK1 may serve biomarker response activity (TK1a) suppression...
Abstract Background: CDK 4/6i have altered the therapeutic landscape of HR+, HER2- MBC, improving progression free and overall survival (PFS OS) compared to endocrine therapy (ET) alone. Despite durable responses in a large majority patients, treatment response monitoring this population has historically included numerous serial blood-based imaging studies at frequent time points. There is growing global interest utilizing novel non-invasive biomarker-driven disease assessments improve...
Abstract Background: ctDNA has shown promise as a prognostic biomarker in early-stage solid tumors. Current breast cancer clinical guidelines do not recommend routine screening for metastatic disease outside of features suggestive recurrence. The detection may be useful the management patients to identify who are at high risk Methods: Patients with stage II or III TNBC undergoing neoadjuvant docetaxel and carboplatin chemotherapy on trial (NCT02124902) followed by surgery were included this...
<p>Supplementary Figure S1. High bTMB is associated with the presence of specific mutations.Supplementary S2. ROC analysis to determine optimal cutoff.Supplementary S3. correlation between determined from WES and a 152-gene targeted sequencing panel.Supplementary S4. Association high cfDNA yield shorter PFS.Supplementary S5. baseline tumor fraction S6. scores are not sites metastatic spread.Supplementary S7. Specific oncogenic signaling pathways more frequently altered inpatients bCNB...